Gundert-Remy U, Weber E, Lam G, Chiou W L, Mann W, Aynilian G H
Eur J Clin Pharmacol. 1981;20(6):459-63. doi: 10.1007/BF00542100.
A dose-ranging pharmacokinetic study of buflomedil was carried out in eight subjects to determine the pharmacokinetic parameters of the drug after oral and intravenous administration. Based on AUC infinity analyses, the pharmacokinetics of buflomedil were found to be linear within the dose ranges studied (50 to 200 mg for i. v. injection and 150 to 450 mg for oral administration). In the oral study, the mean biological half-life of the drug was 2.97 h, while after intravenous dose it was 3.25 h. The apparent volume of distribution after the pseudodistribution equilibrium (Fd beta) and volume of distribution at the steady state (Vdss) were 1.43 +/- 0.24 l/kg and 1.32 +/- 0.26 l/kg, respectively. The mean urinary recovery of intact drug and the metabolite, paradesmethyl buflomedil, after intravenous dosing, were 23.6% and 18.7%, respectively, while after oral dosing, they were 18% and 14.8%, respectively. On the average, 72% of the dose was observed into the systemic circulation after oral administration. This level of bioavailability was attributed to the hepatic first-pass effect.
对8名受试者进行了丁咯地尔的剂量范围药代动力学研究,以确定该药物经口服和静脉给药后的药代动力学参数。基于AUC无穷大分析,发现在所研究的剂量范围内(静脉注射50至200mg,口服150至450mg),丁咯地尔的药代动力学呈线性。在口服研究中,该药物的平均生物半衰期为2.97小时,而静脉给药后为3.25小时。伪分布平衡后的表观分布容积(Fdβ)和稳态分布容积(Vdss)分别为1.43±0.24l/kg和1.32±0.26l/kg。静脉给药后,完整药物和代谢物对羟基丁咯地尔的平均尿回收率分别为23.6%和18.7%,而口服给药后分别为18%和14.8%。口服给药后,平均有72%的剂量进入体循环。这种生物利用度水平归因于肝脏首过效应。